Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection
Public ClinicalTrials.gov record NCT00117689. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Controlled, Multi-Center Study of Thymoglobulin Induction Therapy With a Calcineurin Inhibitor Sparing Regimen in Liver Transplant Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study involves the use of a drug called Thymoglobulin, which is approved in the US to treat kidney transplant rejection and in Canada to treat and prevent kidney transplant rejection. This study will evaluate the effect of Thymoglobulin induction therapy and reduced doses of calcineurin inhibitors on the incidence of liver rejection and will provide a basis for future evaluations of Thymoglobulin as an immunosuppressive agent to help decrease the incidence of liver transplant rejection. Subjects meeting all inclusion and exclusion criteria are eligible to participate in this study. Approximately 75 study subjects from up to 18 transplant centers in the United States and Canada will be enrolled in this 12-month study.
Study identification
- NCT ID
- NCT00117689
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 75 participants
Conditions and interventions
Interventions
- Thymoglobulin Biological
- Corticosteroid Drug
- Tacrolimus Drug
- Mycophenolate Mofetil Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2005
- Primary completion
- Nov 30, 2007
- Completion
- Nov 30, 2007
- Last update posted
- Mar 17, 2015
2005 – 2007
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama, Birmingham | Birmingham | Alabama | 35294 | — |
| USC University Hospital | Los Angeles | California | 90033 | — |
| University of California, San Fransisco Hospital | San Francisco | California | 94143 | — |
| University of Colorado Hospital and Health Sciences Center | Denver | Colorado | 80262 | — |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Fairview University Medical Center | Minneapolis | Minnesota | 55455 | — |
| Washington University Medical Center | St Louis | Missouri | 63110 | — |
| University of Nebraska | Omaha | Nebraska | 68198 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45267 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| University of Texas Health Science Center at San Antonio, University Hospital | San Antonio | Texas | 78229 | — |
| VCU Medical Center | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00117689, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2015 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00117689 live on ClinicalTrials.gov.